Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck
The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and neck.
Squamous Cell Carcinoma of Head and Neck
DRUG: Pemetrexed
Overall response rate, 6 weeks
Median progression-free survival, 1 year|Median overall survival, 1 year
The treatment option in patients with platinum-resistant relapsed or metastatic squamous cell carcinoma of head and neck is limited. Previous randomized phase III study showed a borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the efficacy of pemetrexed in salvage setting.